Btk-deficient mice and Btk inhibitor treated rodents exhibit reduced disease progression in animal models of human rheumatoid arthritis (RA) and systemic lupus erythematodes (SLE) [3]. This evidence concerns the gene BTK and systemic lupus erythematosus.